This article is more than 5 years old. Information may no longer be current.

One-year outcomes similar between paclitaxel-, everolimus-eluting stents

Issue: April 2011

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Cardiovascular Research Technologies 2011

At one year, data from the multicenter, retrospective registry REWARDS-TLX have indicated that major adverse CV events were comparable between patients treated with paclitaxel- and everolimus-eluting stents.

In the study, patients were included if they were older than 18 years of age and underwent PCI with a paclitaxel-eluting stent (PES; Taxus Liberte, Boston Scientific) or a everolimus-eluting stent (EES; Xience V, Abbott Vascular), while exclusion criteria forbade patients who were not taking or unable to take antiplatelet therapy. The final study population included 595 patients in the PES arm (age, 64.6 ± 11.3 years) and 600 patients in the EES arm (age, 64.6 ± 11.3 years).

Overall, 54.5% of patients in the PES group and 60.6% of patients in the EES group presented with ACS, with more lesions reported in the EES arm (833 vs. 857). Procedural success was reported in 97.3% of those treated with a PES and 98% of those treated with EES.

According to in-hospital data, there was no difference between both groups regarding death, MI, Q-wave MI, target vessel revascularization (TVR), target lesion revascularization (TLR) and ST. Follow-up at one year showed slightly more favorable results for patients in the EES arm in the composite of all-cause mortality, Q-wave MI and ST but to a non-statistically significant extent (P=.263), as did TVR major adverse CV events (P=.064) and TLR major adverse CV events (P=.223). Similarly, stent thrombosis rates did not differ significantly between arms.

“The REWARDS TLX study could not corroborate the results of the COMPARE trial in terms of Xience V superiority in the major adverse CV events TVR and overall thrombosis rates,” said Ron Waksman, MD, of the Washington Hospital Center, Washington D.C. and course chairman of the Cardiovascular Research Technologies, in his presentation “Additionally, there are no differences in Q-wave MI and overall death within one year. These similarities were sustained in diabetic patients.” – by Brian Ellis

For more information:

• Waksman R. Presented at: Cardiovascular Research Technologies 2011. Feb. 27-March 1, 2011; Washington, D.C.

Disclosure: Dr. Waksman reports having served on advisory boards for Medtronic Vascular, Boston Scientific and Abbott Vascular.

Follow CardiologyToday.com on Twitter.